Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer

Detalles Bibliográficos
Autores principales: Borcoman, Edith, Le Tourneau, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791256/
https://www.ncbi.nlm.nih.gov/pubmed/33437810
http://dx.doi.org/10.21037/atm-20-2656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791256/
https://www.ncbi.nlm.nih.gov/pubmed/33437810
http://dx.doi.org/10.21037/atm-20-2656

Ejemplares similares